178results about "Vaccines" patented technology

Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.

Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3 / CD3 bispecific antibodies. The present application also provides chimeric antigen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3 / CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.

The invention provides methods and compositions for use in treating cancer, which advantageously may be achieved by targeting of the tumor microenvironment.

To provide methods and compositions for use in treating cancer, which may be achieved by targeting of a tumor microenvironment.SOLUTION: The invention provides an immune cell engineered to express: (a) a chimeric antigen receptor (CAR) polypeptide including an extracellular domain including a first antigen-binding domain that binds to a first antigen and a second antigen-binding domain that binds to a second antigen; and (b) a bispecific T cell engager (BiTE), wherein the BiTE binds to a target antigen and a T cell antigen.SELECTED DRAWING: Figure 1

A therapeutic agent for a metastatic brain tumor comprising, as an active component, an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond and / or a method of treatment for a metastatic brain tumor, comprising administering the antibody-drug conjugate to a subject in need of the treatment for a metastatic brain tumor.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

Treatment of Cancer Methods for treatment of cancer, in particular soft tissue sarcomas (STS), are described, as well as compounds, compositions, and combined preparations for use in such methods. An effective amount of: a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; a programmed cell death protein-1 (PD-1) pathway inhibitor; and radiotherapy, is administered to a subject. Optionally the subject has undergone, is undergoing, or is to undergo, surgery for treatment of the cancer. A clinical trial study is described in which a triple combination of LAG-3 derivative eftilagimod alpha, a PD-1 pathway inhibitor, and radiotherapy was administered. The combination was surprisingly effective in the treatment of STS in patients who have completed 10 weeks of treatment, followed by surgery 2-3 weeks later. A substantial number of near complete pathological responses were observed, which are rarely seen in STS patients with standard therapeutic approaches including radiotherapy.

The invention relates to the technical field of biological medicine, and provides a ginseng cell engineering tumor vaccine as well as a preparation method and application thereof. The ginseng cell engineering tumor vaccine comprises an exosome derived from a recombinant ginseng cell capable of expressing a tumor antigen; the recombinant ginseng cell capable of expressing the tumor antigen is obtained by introducing a recombinant plasmid containing tumor antigen DNA into a ginseng cell. According to the invention, ginseng cells in Chinese herbal medicines are taken as host cells for recombinant expression of tumor antigens, large-scale production of tumor vaccines can be realized through construction of an engineering recombinant cell system, biocompatibility and uniformity of the vaccines can be maintained, and safety risks can be reduced. Meanwhile, the prepared tumor antigen recombinant expression ginseng cell exosome can integrate the antigen, an adjuvant and a carrier, and the antigen phagocytosis, maturation and antigen peptide presentation capabilities of APCs are enhanced.

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether a modification in a peptide or polypeptide, such as a tumor-associated neoantigen, is immunogenic. The methods of the present invention are particularly suitable for providing a vaccine specific to a patient's tumor and, therefore, are suitable for use in the context of personalized cancer vaccines.

The present disclosure provides methods and compositions for genetically modifying lymphocytes, such as T cells and / or NK cells, in shorter time periods than previously possible, and / or in whole blood or components thereof. In some embodiments, a lymphocyte-depletion filter assembly is used before or after forming a reaction mixture, and the lymphocytes are contacted with recombinant retroviral particles in a closed system to genetically modify the lymphocytes.

The invention discloses an SARS-Cov-2 protein gene and a corn endosperm expression vector of the SARS-Cov-2 protein gene. The RBD gene is an RBD protein gene optimized by corn codons, a signal peptide is added to the N terminal, a 2XStrepII-3XFlag tag is added to the C terminal, and a TEV cutting site is added between the RBD and the tag; or, a signal peptide is added to the N end of the S protein gene optimized by corn codons, a 2XStrepII-3XFlag tag is added to the C end, an amino acid sequence RRAR is mutated into GSAS, KV is mutated into PP, a transmembrane structural domain at the C end of the S protein is deleted, and a fibrin trimerization motif is added. The optimized RBD protein and S protein can be successfully expressed and efficiently purified in corn seeds, and the high-yield plant-based platform shows huge potential in the aspects of basic research and application, diagnosis method development and vaccine production.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

The invention relates to a method for constructing an obligate anaerobic Salmonella strain, the obligate anaerobic Salmonella strain constructed by using said method, and the use thereof in tumor therapy.

The present invention relates to the fields of molecular biology, virology, immunology and medicine, and in particular to a preparation method for a castrating AP205 virus-like particle subunit vaccine.

A stabilized formulation for immunoglobulin A and other biological therapeutic proteins, comprising at least one pH buffering agent at about pH 5 to about 8, an optional non-ionic surfactant, and one or more optional stabilizers selected from the group consisting of amino acids, sugars / polyols, chloride salts, carboxylic acids, detergents, native proteins, protein expression extracts, and mixtures thereof. [Selected Figure] Figure 1

The present invention relates to the definition of a pool of antigenic sperm peptides of high species specificity for the regulation of water vole (Arvicola terrestris scherman) populations by a vaccine approach. Figure 1

The invention provides anti-Ara h 2 antibodies (e.g., an anti-Ara h 2 neutralizing antibody) and methods of using the same, e.g., for treating and / or preventing peanut allergy or sensitivity. Also provided herein are anti-Ara h 2 antibodies and methods of using the same, e.g., for diagnostics and methods of monitoring peanut oral immunotherapy.

The invention discloses a novel coronavirus variant RBD protein gene and application thereof. The method comprises the following steps: firstly, respectively constructing recombinant plant expression vectors pGt1-RBD and pGt1-RBDopt containing RBD and RBDopt genes, carrying out agrobacterium-mediated transformation to obtain a T0-generation transgenic rice plant, and carrying out T0-T3-generation screening and identification to obtain a transgenic rice plant capable of stably expressing RBD protein. The RBD protein is successfully expressed in rice endosperm and is subjected to N-glycosylation modification, and the content of the RBD protein in pGt1: RBDopt is obviously higher than that of pGt1: RBD. The pGt1:: RBDopt transgenic rice flour suspension is orally taken into an intragastric mouse, and experimental results show that the transgenic rice pGt1:: RBDopt can be used for developing oral vaccines of new crown vaccines and has a good application prospect.

This new chimeric antigen receptor (CAR) T-cell therapy effectively treats cancer while minimizing the risk of dangerous inflammatory responses such as cytokine release syndrome. [Solution] An isolated nucleic acid sequence encoding a CAR, wherein the CAR includes an antigen-binding domain specific to glypican 3 (GPC3), the antigen-binding domain has an equilibrium dissociation constant (KD) of approximately 100 nanomoles (nM) or less, and the CAR construct provides an isolated nucleic acid sequence that does not induce cytokine production in GPC3-expressing cells.

To provide vaccines which are specific to a patient's tumor and are potentially useful for immunotherapy of a primary tumor and tumor metastasis.SOLUTION: In one aspect, the present invention relates to a method for producing individualized vaccines for cancer, comprising (a) identifying cancer specific somatic mutation in a tumor sample of a cancer patient to provide a patient's cancer mutation signature, and (b) providing a vaccine characterized by the cancer mutation signature obtained in step (a). In a further aspect, the invention relates to a vaccine that can be obtained by the method.SELECTED DRAWING: None

The invention belongs to the technical field of biological genetic transformation, and relates to a method for preparing recombinant foreign protein based on transient expression of fruits of cucurbitaceae crops. The efficient expression of the foreign protein is realized through the processes of constructing an instantaneous transformation vector, infecting fruits with agrobacterium and purifying the protein. The method overcomes the defects of high cost and low purity of a traditional tobacco transient expression system, has the advantages of easily available raw materials, large biomass, edibility, high safety and the like, and provides a new way for low-cost large-scale production of recombinant proteins.

The present invention relates to antigen-based immunotherapy targeting interleukin 13 receptor alpha 2 (IL13RA2), BIRC5 and / or FOXM1 for treatment of adrenal cancers. In particular, the present invention provides the use of a (poly)peptide comprising an epitope of IL13RA2, BIRC5 and / or FOXM1 or a sequence variant thereof for treatment of an adrenal cancer. Moreover, the present invention also provides combinations of the (poly)peptide comprising an epitope of IL13RA2, BIRC5 and / or FOXM1 or a sequence variant thereof with (poly)peptides comprising other epitopes or sequence variants thereof for treatment of adrenal cancers.

The present invention relates to the production of modified influenza vial proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.

The present invention provides phagocytic particles for treating or preventing cancer in a subject, wherein the phagocytic particle comprises a core and a neoantigen construct tightly associated with the core, and wherein the neoantigen construct comprises a neoepitope peptide having an amino acid sequence corresponding to the amino acid sequence of a portion of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the portion of the protein or peptide has at least one somatically mutated amino acid. The present invention also relates to an injectable pharmaceutical composition for treating or preventing cancer.

The present invention relates to a method of producing a binder-toxin fusion protein comprising at least, one protein binder selected from the group consisting of an antibody, an antibody fragment or derivative retaining target binding capacity, or an antibody mimetic, optionally, a peptide linker, and at least one protein toxin or protein protoxin. The method comprises the steps of: contacting a plant cell or a whole plant with a nucleic acid construct comprising in operational linkage at least the following (A) at least one polynucleotide encoding for the protein binder, or a target binding chain or domain thereof, and either B1) a polynucleotide encoding for a cleavable peptide linker and a polynucleotide encoding for a protein toxin, or B2) a polynucleotide encoding for a protein protoxin, which protoxin comprises a cleavable domain for activation thereof, allowing the construct to integrate into the nucleus of the plant cell, or of one or more cells of the whole plant, and expressing the fusion protein encoded by the nucleic acid construct (Fig. 7).

The present invention refers to the use of recombinant Mycobacterium strains encoding the A subunit of the heat-labile LT toxin from mutated Escherichia coli, in the manufacture of an immunobiological composition for the prevention and / or treatment of cancer in animals. Preferably, the mutation is at position 63 from serine to lysine. The present invention also provides immunobiological compositions comprising said strains for use in the prevention and / or treatment of cancer. At last, the present invention refers to methods for the prevention and / or treatment of cancer, comprising the administration of said strains to a subject in need thereof. In particular, said cancer is bladder cancer.

The present invention relates to a method for obtaining an antibody or an antigen-binding fragment thereof that specifically binds to a tumor sample and is directed against the tumor sample, the method comprising: administering autologous dendritic cells to an individual; obtaining immune cells and a tumor sample from the individual; constructing an antibody library of the immune cells; and screening the antibody library to obtain an antibody or a fragment thereof that specifically binds to the tumor sample and is directed against the tumor sample. The present invention also relates to a method for engineering immune cells, an antibody or an antigen-binding fragment thereof that specifically binds to a tumor sample and is directed against the tumor sample, and uses thereof.

To provide methods and compositions for genetically modifying lymphocytes, for example, T cells and / or NK cells in a shorter time than before and / or in whole blood or a blood component.SOLUTION: The disclosure provides methods and compositions for genetically modifying lymphocytes, for example, T cells and / or NK cells in a shorter time than before, and / or in whole blood or in a blood component. In some embodiments, a lymphodepletion filter assembly is used before or after a reaction mixture is formed, and the lymphocytes are brought into contact with recombinant retrovirus particles in a closed system to genetically modify the lymphocytes.SELECTED DRAWING: None

The invention provides a reagent, a kit for measuring an antigen, and a method for measuring an antigen using an antibody capable of reducing a non-specific reaction. The immunoassay reagent comprises an humanized antibody against a target substance.